In addition, PCI mediated delivery of other non-targeting therapeutics has been demonstrated in vivo, i.e. bleomycin, p53-based gene therapeutics and siRNA [30], [35]–[37].The DDS system presented here may therefore reduce the dosage of anti-cancer therapeutics that is needed to achieve a satisfactory outcome. This evidence concerns the gene TP53 and cancer.